Literature DB >> 20929961

Riboflavin-responsive oxidative phosphorylation complex I deficiency caused by defective ACAD9: new function for an old gene.

Mike Gerards1, Bianca J C van den Bosch, Katharina Danhauser, Valérie Serre, Michel van Weeghel, Ronald J A Wanders, Gerry A F Nicolaes, Wim Sluiter, Kees Schoonderwoerd, Hans R Scholte, Holger Prokisch, Agnès Rötig, Irenaeus F M de Coo, Hubert J M Smeets.   

Abstract

Mitochondrial complex I deficiency is the most common oxidative phosphorylation defect. Mutations have been detected in mitochondrial and nuclear genes, but the genetics of many patients remain unresolved and new genes are probably involved. In a consanguineous family, patients presented easy fatigability, exercise intolerance and lactic acidosis in blood from early childhood. In muscle, subsarcolemmal mitochondrial proliferation and a severe complex I deficiency were observed. Exercise intolerance and complex I activity was improved by a supplement of riboflavin at high dosage. Homozygosity mapping revealed a candidate region on chromosome three containing six mitochondria-related genes. Four genes were screened for mutations and a homozygous substitution was identified in ACAD9 (c.1594 C>T), changing the highly conserved arginine-532 into tryptophan. This mutation was absent in 188 ethnically matched controls. Protein modelling suggested a functional effect due to the loss of a stabilizing hydrogen bond in an α-helix and a local flexibility change. To test whether the ACAD9 mutation caused the complex I deficiency, we transduced fibroblasts of patients with wild-type and mutant ACAD9. Wild-type, but not mutant, ACAD9 restored complex I activity. An unrelated patient with the same phenotype was compound heterozygous for c.380 G>A and c.1405 C>T, changing arginine-127 into glutamine and arginine-469 into tryptophan, respectively. These amino acids were highly conserved and the substitutions were not present in controls, making them very probably pathogenic. Our data support a new function for ACAD9 in complex I function, making this gene an important new candidate for patients with complex I deficiency, which could be improved by riboflavin treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20929961     DOI: 10.1093/brain/awq273

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  29 in total

1.  A Patient with Complex I Deficiency Caused by a Novel ACAD9 Mutation Not Responding to Riboflavin Treatment.

Authors:  Jessica Nouws; Flemming Wibrand; Mariël van den Brand; Hanka Venselaar; Morten Duno; Allan M Lund; Simon Trautner; Leo Nijtmans; Elsebet Ostergard
Journal:  JIMD Rep       Date:  2013-08-31

2.  Complex I assembly function and fatty acid oxidation enzyme activity of ACAD9 both contribute to disease severity in ACAD9 deficiency.

Authors:  Manuel Schiff; Birgit Haberberger; Chuanwu Xia; Al-Walid Mohsen; Eric S Goetzman; Yudong Wang; Radha Uppala; Yuxun Zhang; Anuradha Karunanidhi; Dolly Prabhu; Hana Alharbi; Edward V Prochownik; Tobias Haack; Johannes Häberle; Arnold Munnich; Agnes Rötig; Robert W Taylor; Robert D Nicholls; Jung-Ja Kim; Holger Prokisch; Jerry Vockley
Journal:  Hum Mol Genet       Date:  2015-02-26       Impact factor: 6.150

Review 3.  Mitochondrial disorders caused by mutations in respiratory chain assembly factors.

Authors:  Francisca Diaz; Heike Kotarsky; Vineta Fellman; Carlos T Moraes
Journal:  Semin Fetal Neonatal Med       Date:  2011-06-15       Impact factor: 3.926

Review 4.  Challenges of bringing next generation sequencing technologies to clinical molecular diagnostic laboratories.

Authors:  Lee-Jun C Wong
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

5.  Lethal Neonatal Progression of Fetal Cardiomegaly Associated to ACAD9 Deficiency.

Authors:  Jennifer Lagoutte-Renosi; Isabelle Ségalas-Milazzo; Marie Crahes; Florian Renosi; Laurence Menu-Bouaouiche; Stéphanie Torre; Caroline Lardennois; Marlène Rio; Stéphane Marret; Carole Brasse-Lagnel; Annie Laquerrière; Soumeya Bekri
Journal:  JIMD Rep       Date:  2015-10-17

Review 6.  Treatment options for lactic acidosis and metabolic crisis in children with mitochondrial disease.

Authors:  Katharina Danhauser; Jan A M Smeitink; Peter Freisinger; Wolfgang Sperl; Hemmen Sabir; Berit Hadzik; Ertan Mayatepek; Eva Morava; Felix Distelmaier
Journal:  J Inherit Metab Dis       Date:  2015-02-17       Impact factor: 4.982

7.  Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis.

Authors:  Daniele Ghezzi; Enrico Baruffini; Tobias B Haack; Federica Invernizzi; Laura Melchionda; Cristina Dallabona; Tim M Strom; Rossella Parini; Alberto B Burlina; Thomas Meitinger; Holger Prokisch; Ileana Ferrero; Massimo Zeviani
Journal:  Am J Hum Genet       Date:  2012-05-17       Impact factor: 11.025

8.  Mitochondrial encephalomyopathy due to a novel mutation in ACAD9.

Authors:  Caterina Garone; Maria Alice Donati; Michele Sacchini; Beatriz Garcia-Diaz; Claudio Bruno; Sarah Calvo; Vamsi K Mootha; Salvatore Dimauro
Journal:  JAMA Neurol       Date:  2013-09-01       Impact factor: 18.302

9.  Combined OXPHOS complex I and IV defect, due to mutated complex I assembly factor C20ORF7.

Authors:  Ann Saada; Shimon Edvardson; Avraham Shaag; Wendy K Chung; Reeval Segel; Chaya Miller; Chaim Jalas; Orly Elpeleg
Journal:  J Inherit Metab Dis       Date:  2011-05-24       Impact factor: 4.982

10.  Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cells.

Authors:  Dana Marcus; Michal Lichtenstein; Ann Saada; Haya Lorberboum-Galski
Journal:  Mol Med       Date:  2013-07-24       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.